Abstract
The fluorinated pyrimidine nucleoside, 5′-deoxy-5-fluorouridine (5′-dFUrd) has been shown to effectively attenuate the progress of cachexia in the murine adenocarcinomas MAC16 and colon 26 as well as in the human uterine cervical carcinoma xenograft, Yumoto. Although concomitant inhibition of tumour growth was observed in all three models this was not sufficient to account for the preservation of body weight. An attempt has been made to correlate the anti-cachectic activity of 5′-dFUrd with the presence of a tumour produced proteolysis-inducing factor (PIF), thought to be responsible for the development of cachexia in the MAC16 model. Two variants of colon 26 adenocarcinoma were employed, clone 20 which produces profound cachexia, and clone 5 which produces no change in body weight in recipient animals. Mice bearing the colon 26, clone 20 variant showed evidence for the presence of PIF in tumour, serum and urine, while there was no evidence for the presence of PIF in tumour or body fluids of mice bearing the clone 5 tumours. Treatment of animals bearing the clone 20 variant with 5′-dF Urd led to the disappearance of PIF from the tumour, serum and urine concomitant with the attenuation of the development of cachexia. The human cervical carcinoma, Yumoto, which also induced cachexia in recipiant animals, showed expression of PIF in tumour, serum and urine in control and vehicle-treated mice, but was absent in mice treated with 5′-dFUrd. Thus in these experimental models cachexia appears to be correlated with the presence of PIF. © 2000 Cancer Research Campaign
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Beck SA and Tisdale MJ (1987) Production of lipolytic and proteolytic factors by a murine tumor-producing cachexia in the host. Cancer Res 47: 5919–5923
Beck SA, Smith KL and Tisdale MJ (1991) Anticachectic and antitumor effect of eicosapentaenoic acid and its effect on protein turnover. Cancer Res 51: 6089–6093
Beulter B and Cerami A (1986) Cachectin and tumor necrosis factor as two sides of the same biological coin. Nature 320: 584–588
Cariuk P, Lorite MJ, Todorov PT, Field WN, Wigmore SJ and Tisdale MJ (1997) Induction of cachexia in mice by a product isolated from the urine of cachectic cancer patients. Br J Cancer 76: 606–613
Double JA and Bibby MC (1989) Therapeutic index: a vital component in selection of anticancer agents for clinical trial. J Natl Cancer Inst 81: 988–994
Eda H, Tanaka Y and Ishitsuka H (1991) 5′-Deoxy-5-flurouridine improves cachexia by a mechanism independent of its antiproliferative action in colon 26 adenocarcinoma-bearing mice. Cancer Chemother Pharmacol 29: 1–6
Fujiki F, Mukaida N, Hirose K, Ishida H, Harada A, Ohno S, Bluethmann H, Kawakami M, Akiyama M, Sone S and Matsushima K (1997) Prevention of adenocarcinoma colon 26-induced cachexia by interleukin 10 gene transfer. Cancer Res 57: 94–99
Fujimoto-Ouchi K, Tamura S, Mori K, Tanaka Y and Ishitsuka H (1995) Establishment and characterization of cachexia-inducing and non-inducing clones of murine colon 26 carcinoma. Int J Cancer 61: 522–528
Lorite MJ, Cariuk P and Tisdale MJ (1997) Induction of muscle protein degradation by a tumour factor. Br J Cancer 76: 1035–1040
Lorite MJ, Thompson MG, Drake JL, Carling G and Tisdale MJ (1998) Mechanism of muscle protein degradation induced by a cancer cachectic factor. Br J Cancer 78: 850–856
Matthys P, Heremans H, Opdenakker G and Billiau A (1991) Anti-interferon-γ antibody treatment, growth of Lewis lung tumours in mice and tumour-associated cachexia. Eur J Cancer 27: 182–187
Moldawer LL, Anderson C, Gelin J and Lundholm KG (1988) Regulation of food intake and hepatic protein synthesis by recombinant-derived cytokines. Am J Physiol 254: G450–G456
Mori M, Yamaguchi K, Honda S, Nagasaki K, Ueda M, Abe O and Abe K (1991) Cancer cachexia syndrome developed in nude mice bearing melanoma cells producing leukemia inhibitory factor. Cancer Res 51: 6656–6659
Mulligan HD, Mahony SM, Ross JA and Tisdale MJ (1992) Weight loss in a murine cachexia model is not associated with the cytokines tumour necrosis factor-α or interleukin-6. Cancer Lett 65: 239–243
Soda K, Kawakami M, Kashii K and Miyata M (1995) Manifestations of cancer cachexia induced by colon 26 adenocarcinoma are not fully ascribable to interleukin-6. Int J Cancer 62: 332–336
Strassman G, Fong M, Kenney JS and Jacob CO (1992) Evidence for the involvement of interleukin 6 in experimental cancer cachexia. J Clin Invest 89: 1681–1684
Tamura S, Fujimoto-Ouchi K, Mori K, Endo M, Matsumoto T, Eda H, Tanaka Y, Ishitsuka H, Tokita H and Yamaguchi K (1995) Involvement of human interleukin 6 in experimental cachexia induced by a human uterine cervical carcinoma xenograft. Clin Cancer Res 1: 1353–1358
Tanaka Y, Eda H, Fujimoto K, Tanaka T, Ishikawa T and Ishitsuka H (1990) Anticachectic activity of 5′-deoxy-5-fluorouridine in a murine tumor cachexia model, colon 26 adenocarcinoma. Cancer Res 50: 4528–4532
Todorov P, Cariuk P, McDevitt T, Coles B, Fearon K and Tisdale M 1996 a) Characterization of a cancer cachectic factor. Nature 379: 739–742
Todorov PT, McDevitt TM, Cariuk P, Coles B, Deacon M and Tisdale MJ 1996 b) Induction of muscle protein degradation and weight loss by a tumor product. Cancer Res 56: 1256–1261
Todorov PT, Deacon M and Tisdale MJ (1997) Structural analysis of a tumor-produced sulfated glycoprotein capable of initiating muscle protein degradation. J Biol Chem 272: 12279–12288
Todorov PT, McDevitt TM, Meyer DJ, Ueyama H, Ohkubo I and Tisdale MJ (1998) Purification and characterization of a tumor lipid-mobilizing factor. Cancer Res 58: 2353–2358
Wigmore SJ, Ross JA, Falconer JS, Plester CE, Tisdale MJ, Carter DC and Fearon KCH (1996) The effect of polyunsaturated fatty acids on the progress of cachexia in patients with pancreatic cancer. Nutrition 12: S27–S30
Yasumoto K, Nukaida N, Harada A, Kuno K, Akiyama M, Nakashima E, Fujioka N, Mai M, Kasahara T, Fujimoto-Ouchi K, Mori K, Tanaka Y and Matsushima K (1995) Molecular analysis of the cytokine network involved in cachexia in colon 26 adenocarcinoma-bearing mice. Cancer Res 55: 921–927
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Hussey, H., Todorov, P., Field, W. et al. Effect of a fluorinated pyrimidine on cachexia and tumour growth in murine cachexia models: relationship with a proteolysis inducing factor. Br J Cancer 83, 56–62 (2000). https://doi.org/10.1054/bjoc.2000.1278
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1054/bjoc.2000.1278
Keywords
This article is cited by
-
Capecitabine improves cancer cachexia and normalizes IL-6 and PTHrP levels in mouse cancer cachexia models
Cancer Chemotherapy and Pharmacology (2007)
-
Signal transduction pathways involved in proteolysis-inducing factor induced proteasome expression in murine myotubes
British Journal of Cancer (2003)